ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
AbbVie Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$282.68−2.74 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $500.63B
- P/E (TTM)
- 79.9
- Dividend yield
- 2.35%
AbbVie statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | AbbVie | Industry median |
|---|---|---|
| Market Cap | $499.53B | $197.05M |
| Enterprise Value | $563.83B | $106.56M |
| PE Ratio | 79.85 | 20.52 |
| PS Ratio | 7.76 | 3.93 |
| P/FCF Ratio | 27.43 | 18.25 |
| P/OCF Ratio | 25.61 | 13.78 |
Enterprise value
| Measure | AbbVie | Industry median |
|---|---|---|
| EV / Sales | 8.76 | 2.69 |
| EV / EBITDA | 33.42 | 14.86 |
| EV / EBIT | 33.42 | 19.00 |
| EV / FCF | 30.96 | 21.02 |
Income (trailing twelve months)
| Measure | AbbVie | Industry median |
|---|---|---|
| Revenue | $64.39B | $57.94M |
| Gross Profit | $46.02B | $90.47M |
| Operating Income | $16.87B | -$21.44M |
| Pretax Income | $8.70B | -$14.45M |
| Net Income | $6.31B | -$22.46M |
| EBITDA | $16.87B | -$16.91M |
| EPS (Diluted) | $3.54 | -$0.83 |
Margins
| Measure | AbbVie | Industry median |
|---|---|---|
| Gross Margin | 71.5% | 52.3% |
| Operating Margin | 26.2% | -44.5% |
| Pretax Margin | 13.5% | -13.0% |
| Profit Margin | 9.80% | -39.2% |
| EBITDA Margin | 26.2% | -31.3% |
| FCF Margin | 28.3% | -8.85% |
Returns
| Measure | AbbVie | Industry median |
|---|---|---|
| Return on Assets (ROA) | 4.63% | -41.0% |
| Return on Invested Capital (ROIC) | 20.1% | -32.0% |
| Return on Capital Employed (ROCE) | 18.0% | -37.8% |
Growth
| Measure | AbbVie | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 10.4% | 6.01% |
| Net Income Growth (YoY) | 67.7% | -37.7% |
| EPS Growth (YoY) | 68.6% | -29.2% |
| FCF Growth (YoY) | -0.16% | 2.34% |
| Revenue Growth (3Y CAGR) | 1.75% | 2.25% |
| Revenue Growth (5Y CAGR) | 5.95% | 6.42% |
| EPS Growth (3Y CAGR) | -29.1% | -0.17% |
| EPS Growth (5Y CAGR) | -2.80% | 3.77% |
Balance sheet
| Measure | AbbVie | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $6.57B | $62.42M |
| Total Debt | $70.82B | $120.13M |
| Net Cash (Debt) | -$64.25B | $15.68M |
| Net Cash Per Share | -$36.36 | $0.65 |
| Equity (Book Value) | -$5.94B | $48.79M |
| Book Value Per Share | -$3.36 | $1.36 |
| Tangible Book Value | -$90.59B | $23.06M |
| Working Capital | -$7.97B | $75.77M |
Financial position
| Measure | AbbVie | Industry median |
|---|---|---|
| Current Ratio | 0.81 | 3.30 |
| Quick Ratio | 0.49 | 2.39 |
| Debt / EBITDA | 4.20 | 3.35 |
| Debt / FCF | 3.89 | 5.05 |
| Net Debt / EBITDA | 3.81 | 2.22 |
| Interest Coverage | 5.79 | -7.12 |
Cash flow (trailing twelve months)
| Measure | AbbVie | Industry median |
|---|---|---|
| Operating Cash Flow | $19.51B | -$12.35M |
| Capital Expenditures | -$1.30B | -$1.06M |
| Free Cash Flow | $18.21B | -$20.28M |
| FCF Per Share | $10.30 | -$0.41 |
Efficiency
| Measure | AbbVie | Industry median |
|---|---|---|
| Asset Turnover | 0.47 | 0.38 |
| Inventory Turnover | 3.64 | 2.67 |
| Revenue Per Employee | $1.13M | $398.96K |
| Profits Per Employee | $110.70K | -$732.08K |
| Employee Count | 57,000 | 73 |
Dividends and yields
| Measure | AbbVie | Industry median |
|---|---|---|
| Earnings Yield | 1.26% | -21.2% |
| FCF Yield | 3.65% | -7.64% |
| Dividend Yield | 2.35% | 1.83% |
| Buyback Yield | 0.30% | -0.58% |
| Shareholder Yield | 2.65% | 0.00% |
| Dividend Per Share | $6.65 | $0.83 |
| Dividend Growth (YoY) | 5.72% | 2.37% |
| Years of Dividend Growth | 11 | 0 |
| Payout Ratio | 189.8% | 47.7% |
| FCF Payout Ratio | 65.8% | 51.6% |
Shares
| Measure | AbbVie | Industry median |
|---|---|---|
| Shares Outstanding | 1,767,120,000 | 59,128,900 |
| Shares Change (YoY) | 0.03% | 11.1% |
| Float | 1,765,580,000 | 48,744,500 |
| Shares Held by Insiders | 0.09% | 11.8% |
| Shares Held by Institutions | 75.6% | 59.4% |
Taxes
| Measure | AbbVie | Industry median |
|---|---|---|
| Income Tax | $2.38B | $91.50K |
| Effective Tax Rate | 27.4% | 20.6% |
Scores
| Measure | AbbVie | Industry median |
|---|---|---|
| Altman Z-Score | 2.76 | 0.10 |
| Piotroski F-Score | 8 | 4 |
Calculated by StockData from AbbVie's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.